罗沙司他胶囊与重组人促红素治疗肾性贫血的效果及预后比较(4)
[18] Chen N,Qian J,Chen J,et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China [J]. Nephrol Dial Transplant,2017,32(8):1373-1386.
[19] Chen N,Hao C,Peng X,et al. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis [J]. N Engl J Med,2019,381(11):1001-1010.
[20] Provenzano R,Besarab A,Sun CH,et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat(FG-4592)for the treatment of anemia in patients with CKD [J]. Clin J Am Soc Nephrol,2016,11(6):982-991.
[21] 常園园,范秋灵.Erythroferrone-铁调素轴在肾性贫血中的研究进展[J].中国临床研究,2017,30(2):268-271.
[22] 李月琼,刘雨田,吕德.重组人促红素联合多糖铁治疗血液透析后肾性贫血[J].深圳中西医结合杂志,2018, 28(22):156-157.
[23] Chen N,Hao C,Liu BC,et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis [J]. N Engl J Med,2019,381(11):1011-1022.
[24] 周雅萍,李凯.治疗肾性贫血新药罗沙司他[J].药物评价研究,2018,41(9):1743-1748.
(收稿日期:2019-12-01 本文编辑:刘明玉), http://www.100md.com(李宏彬 梁军 马强)
[19] Chen N,Hao C,Peng X,et al. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis [J]. N Engl J Med,2019,381(11):1001-1010.
[20] Provenzano R,Besarab A,Sun CH,et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat(FG-4592)for the treatment of anemia in patients with CKD [J]. Clin J Am Soc Nephrol,2016,11(6):982-991.
[21] 常園园,范秋灵.Erythroferrone-铁调素轴在肾性贫血中的研究进展[J].中国临床研究,2017,30(2):268-271.
[22] 李月琼,刘雨田,吕德.重组人促红素联合多糖铁治疗血液透析后肾性贫血[J].深圳中西医结合杂志,2018, 28(22):156-157.
[23] Chen N,Hao C,Liu BC,et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis [J]. N Engl J Med,2019,381(11):1011-1022.
[24] 周雅萍,李凯.治疗肾性贫血新药罗沙司他[J].药物评价研究,2018,41(9):1743-1748.
(收稿日期:2019-12-01 本文编辑:刘明玉), http://www.100md.com(李宏彬 梁军 马强)